Global Anti-TIGIT Antibody Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anti-TIGIT Antibody Market Insights, Forecast to 2034
A human monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), with potential immune checkpoint inhibitory activity.
Market Analysis and InsightsGlobal Anti-TIGIT Antibody Market
Global Anti-TIGIT Antibody market is expected to reach to US$ 367.4 million in 2024, with a positive growth of %, compared with US$ 324.8 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Anti-TIGIT Antibody industry is evaluated to reach US$ 787.1 million in 2029. The CAGR will be 13.5% during 2024 to 2029.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a protein receptor found on various immune cells, including T cells and natural killer (NK) cells. It plays a role in regulating immune responses, and targeting TIGIT has emerged as a potential therapeutic strategy for cancer and autoimmune diseases.
Clinical trials were underway to evaluate the safety and efficacy of anti-TIGIT antibodies either as monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies). Promising results were reported from early-stage trials, showing potential benefits in various solid tumors, including lung cancer, melanoma, and gastrointestinal cancers.
The market for anti-TIGIT antibodies was expected to grow as more clinical data became available.
Report Covers
This report presents an overview of global Anti-TIGIT Antibody market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Anti-TIGIT Antibody market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Gilead Sciences
Segment by Type
Monotherapy
Combination Therapy
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Anti-TIGIT Antibody introduction, etc. Anti-TIGIT Antibody Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Anti-TIGIT Antibody
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Market Analysis and InsightsGlobal Anti-TIGIT Antibody Market
Global Anti-TIGIT Antibody market is expected to reach to US$ 367.4 million in 2024, with a positive growth of %, compared with US$ 324.8 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Anti-TIGIT Antibody industry is evaluated to reach US$ 787.1 million in 2029. The CAGR will be 13.5% during 2024 to 2029.
TIGIT (T cell immunoreceptor with Ig and ITIM domains) is a protein receptor found on various immune cells, including T cells and natural killer (NK) cells. It plays a role in regulating immune responses, and targeting TIGIT has emerged as a potential therapeutic strategy for cancer and autoimmune diseases.
Clinical trials were underway to evaluate the safety and efficacy of anti-TIGIT antibodies either as monotherapy or in combination with other immunotherapies, such as checkpoint inhibitors (e.g., anti-PD-1/PD-L1 antibodies). Promising results were reported from early-stage trials, showing potential benefits in various solid tumors, including lung cancer, melanoma, and gastrointestinal cancers.
The market for anti-TIGIT antibodies was expected to grow as more clinical data became available.
Report Covers
This report presents an overview of global Anti-TIGIT Antibody market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Anti-TIGIT Antibody market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Roche
Merck
AstraZeneca
Arcus
Astellas
BeiGene
BMS
Junshi Biosciences
Innovent Biologics
Mereo BioPharma
Seattle Genetics
Hengrui Medicine
Compugen
Gilead Sciences
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Cell Carcinoma
Solid Tumor
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Anti-TIGIT Antibody introduction, etc. Anti-TIGIT Antibody Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Anti-TIGIT Antibody
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices